Among these mechanisms, the synergistic anticancer effect of the histone deacetylase (HDAC) inhibitor or sorafenib and radiation-induced suppression of advanced cancer has been considered one of the probable reasons for poor clinical results [17,18,19]. Here, HDAC9 is linked to cancer.